ALNA stock forecast
Our latest prediction for Allena Pharmaceuticals, Inc.'s stock price was made on the Nov. 6, 2017 when the stock price was at 10.48$.
In the short term (2weeks), ALNA's stock price should outperform the market by 5.56%. During that period the price should oscillate between -2.15% and +3.65%.
In the medium term (3months), ALNA's stock price should outperform the market by 9.81%. During that period the price should oscillate between -3.48% and +8.51%.Get email alerts
Create a solid portfolio with ALNA
About Allena Pharmaceuticals, Inc.
Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults; and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Newton, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.58$ per share.
The book value per share is 3.25$
Three months stock forecastNov. 6, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|